
FDA Clears Tecentriq + Lurbinectedin for First-Line Maintenance in Small Cell Lung Cancer
FDA Approves Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer In a landmark decision for the lung cancer community, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S.…












